Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.37 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.36 |
| ▸ | DHODH | Q02127 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | PTGFR | P43088 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22179952 | 0.88 | NAMPT (0.41) | NAMPTCTNNB1TCF7L2CYP1A2CYP3A4 | |
| SCHEMBL22180268 | 0.88 | NAMPT (0.39) | ADORA1PTGS2NAMPTCTNNB1TCF7L2 | |
| SCHEMBL30738306 | 0.88 | NAMPT (0.38) | NAMPTCTNNB1TCF7L2CYP1A2CYP3A4 | |
| SCHEMBL22179997 | 0.88 | NAMPT (0.38) | NAMPTCTNNB1TCF7L2CYP1A2CYP3A4 | |
| SCHEMBL22179733 | 0.86 | KMT2A (0.43) | PTGS2NAMPT | |
| SCHEMBL29831787 | 0.85 | NAMPT (0.41) | NAMPTCTNNB1TCF7L2CYP1A2CYP3A4 | |
| SCHEMBL28443353 | 0.85 | NAMPT (0.41) | NAMPTCTNNB1TCF7L2CYP1A2CYP3A4 | |
| SCHEMBL30738378 | 0.84 | NPC1 (0.42) | ADORA1PTGS2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL22179956 | 0.84 | NPC1 (0.42) | ADORA1PTGS2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL22180299 | 0.83 | MAP4K4 (0.40) | ADORA1CYP1A2CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166119-B | Substituted aryl compound and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20210395226-A1 | SUBSTITUTED ARYL COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-12-23 | — | — | US | disclosed |
| EP-3904352-A1 | SUBSTITUTED ARYL COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2021-11-03 | — | — | EP | disclosed |
| CN-113166119-A | Substituted aryl compound and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020135210-A1 | SUBSTITUTED ARYL COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2020-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395226-A1 | SUBSTITUTED ARYL COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | ADORA2A, ADORA1, ADORA3 | ADORA1 2/4885PTGS2 2162/4885NAMPT 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.